Current Status of Therapeutic Drug Monitoring of 5-Fluorouracil Prodrugs
In recent years, therapeutic drug monitoring (TDM) of intravenous administration of 5-fluorouracil (5-FU) has resulted in reduced toxicity and improved efficacy. Prodrugs of 5-FU were developed to reduce toxicity, extend the duration of action, and increase tumour selectivity of 5-FU. These drugs ar...
Saved in:
Published in | Anticancer research Vol. 40; no. 8; pp. 4655 - 4661 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Athens
International Institute of Anticancer Research
01.08.2020
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | In recent years, therapeutic drug monitoring (TDM) of intravenous administration of 5-fluorouracil (5-FU) has resulted in reduced toxicity and improved efficacy. Prodrugs of 5-FU were developed to reduce toxicity, extend the duration of action, and increase tumour selectivity of 5-FU. These drugs are important in daily practice because of their ease of administration. Dose adjustment of 5-FU prodrugs by TDM is expected to reduce its toxicity and improve its efficacy. This review focuses on data from a recent study of personalized treatment using TDM of 5-FU and its prodrugs. |
---|---|
Bibliography: | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
ISSN: | 0250-7005 1791-7530 |
DOI: | 10.21873/anticanres.14464 |